Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

949
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
949
Drug Nomenclature01:17

Drug Nomenclature

1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Prodrugs01:30

Prodrugs

2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
2.6K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

706
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
706
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

141
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
141
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in Utilization Management for Oncology Therapies Amongst US Commercial Health Plans: 2017-2024.

JCO oncology practice·2026
Same author

PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice.

International journal of molecular sciences·2026
Same author

The timeliness of health plan drug coverage policy changes to FDA label revisions.

Health affairs scholar·2026
Same author

FDA approvals of specialty drugs, 2000-2024.

Health affairs scholar·2026
Same author

Outcomes of a Phase II Interventional Clinical Trial of Prostate Bed Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features Following Radical Prostatectomy.

International journal of radiation oncology, biology, physics·2026
Same author

Drug Prices, Rebates, and Health Plan Coverage Restrictions.

JAMA network open·2026
Same journal

National Health Expenditure Projections, 2025-34: Strong Utilization Growth Initially, Legislative Impacts Later.

Health affairs (Project Hope)·2026
Same journal

State Medicaid Programs Face Increased Spending On Medicare Premiums.

Health affairs (Project Hope)·2026
Same journal

Not enough time.

Health affairs (Project Hope)·2026
Same journal

Medicaid Tobacco And Nicotine Cessation Treatment Rates Remained Low, 2019-24.

Health affairs (Project Hope)·2026
Same journal

Third-Party Convener Firms And The Rise Of Geographically Dispersed, High-Earning Medicare ACOs.

Health affairs (Project Hope)·2026
Same journal

The Opacity Of Price Transparency.

Health affairs (Project Hope)·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease.

Molly T Beinfeld1, Fariel LaMountain2, William Wong3

  • 1Molly T. Beinfeld (mbeinfeld@tuftsmedicalcenter.org), Tufts University, Boston, Massachusetts.

Health Affairs (Project Hope)
|September 3, 2024
PubMed
Summary
This summary is machine-generated.

Biosimilars are increasingly successful, with recent launches driving significant market competition and savings. By 2022, most payers covered multiple products, leading to biosimilar market share growth and price reductions.

More Related Videos

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

954
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.3K

Related Experiment Videos

Last Updated: Jun 14, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

954
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.3K

Area of Science:

  • Pharmacoeconomics
  • Health Services Research
  • Biopharmaceutical Market Analysis

Background:

  • Biosimilars, near-identical copies of biologic drugs, faced slow initial adoption and savings.
  • Recent biosimilar launches demonstrate improved market success and potential for substantial cost reductions.

Purpose of the Study:

  • To analyze the impact of biosimilar introductions on originator-biosimilar markets between 2017 and 2022.
  • To assess market dynamics and predict future savings based on biosimilar market performance.

Main Methods:

  • Examined market data from 2017-2022 focusing on biosimilar introductions.
  • Analyzed payer coverage policies and market share shifts between originators and biosimilars.
  • Tracked changes in average sales prices within originator-biosimilar markets.

Main Results:

  • Payer policies increasingly favored multiple product choices (originator or biosimilar) as first-line options, reaching 76% by 2022.
  • Biosimilar market share surpassed originators within three years of the first biosimilar launch.
  • Significant declines in average sales prices were observed in originator-biosimilar markets.

Conclusions:

  • The study provides evidence of a maturing and competitive biosimilar market.
  • Increased competition from biosimilars is leading to substantial market savings.
  • Future biosimilar launches are expected to yield significant economic benefits.